Your browser doesn't support javascript.
loading
Quetiapine for the Treatment of Pediatric Delirium.
Caballero, Alexandra; Bashqoy, Ferras; Santos, Laura; Herbsman, Jodi; Papadopoulos, John; Saad, Anasemon.
Afiliación
  • Caballero A; Department of Pharmacy, NYU Langone Health, New York, NY, USA.
  • Bashqoy F; Department of Pharmacy, Hassenfeld Children's Hospital at NYU Langone, New York, NY, USA.
  • Santos L; Hassenfeld Children's Hospital at NYU Langone, New York, NY, USA.
  • Herbsman J; Rusk Rehabilitation, Hassenfeld Children's Hospital at NYU Langone, New York, NY, USA.
  • Papadopoulos J; Department of Pharmacy, NYU Langone Health, New York, NY, USA.
  • Saad A; Department of Pharmacy, Hassenfeld Children's Hospital at NYU Langone, New York, NY, USA.
Ann Pharmacother ; 57(10): 1172-1177, 2023 10.
Article en En | MEDLINE | ID: mdl-36802820
BACKGROUND: Delirium is a common complication of critical illness, with a prevalence of 25% among pediatric intensive care unit (ICU) patients. Pharmacological treatment options for ICU delirium are limited to off-label use of antipsychotics, but their benefit remains uncertain. OBJECTIVE: The purpose of this study was to evaluate quetiapine effectiveness for the treatment of delirium in critically ill pediatric patients and to describe the safety profile of quetiapine. METHODS: A single-center, retrospective review of patients aged ≤ 18 years who screened positive for delirium via the Cornell Assessment of Pediatric Delirium (CAPD ≥ 9) and received ≥ 48 hours of quetiapine therapy was conducted. The relationship between quetiapine and deliriogenic medication doses was evaluated. RESULTS: This study included 37 patients who received quetiapine for the treatment of delirium. The change in sedation requirements before quetiapine initiation to 48 hours after the highest quetiapine dose demonstrated a downward trend; 68% of patients had a decrease in opioid requirements and 43% of patients had a decrease in benzodiazepine requirements. The median CAPD score at baseline was 17 and the median CAPD score at 48 hours after the highest dose was 16. Three patients experienced QTc prolongation (defined as a QTc ≥ 500), although none developed dysrhythmias. CONCLUSION AND RELEVANCE: Quetiapine did not have a statistically significant impact on deliriogenic medication doses. There were minimal changes in QTc and dysrhythmias were not identified. Therefore, quetiapine can be safe to use in our pediatric patients but further studies are needed to find an effective dose.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antipsicóticos / Delirio Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Ann Pharmacother Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antipsicóticos / Delirio Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Ann Pharmacother Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos